Approximately one third of patients with advanced metastatic melanoma responded to ICB using monoclonal antibody (mAb) against PD-1 (anti-PD-1) (Hamid et al., 2013; Robert et al., 2015, 2015; Weber et al., 2015). This evidence concerns the gene PDCD1 and metastatic melanoma.